Naren K. Gursahaney - Oct 12, 2022 Form 4 Insider Report for TERMINIX GLOBAL HOLDINGS INC (TMX)

Role
Director
Signature
/s/ Dirk R. Gardner, Attorney In Fact for Naren Gursahaney
Stock symbol
TMX
Transactions as of
Oct 12, 2022
Transactions value $
-$160,543
Form type
4
Date filed
10/14/2022, 06:58 PM
Previous filing
May 25, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMX Common Stock Disposed to Issuer -44.2K -100% 0 Oct 12, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMX Employee Stock Options (employment right to buy) Disposed to Issuer -$161K -104K -100% $1.54* 0 Oct 12, 2022 Common Stock 104K $36.75 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Naren K. Gursahaney is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Terminix Global Holdings, Inc. ("Terminix") common stock disposed of in connection with the Agreement and Plan of Merger, dated as of December 13, 2021, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of March 14, 2022 (the "Merger Agreement"), by and among Terminix, Rentokil Initial plc ("Rentokil Initial") and certain of Rentokil Initial's subsidiaries. In accordance with the Merger Agreement, at the First Effective Time (as defined in the Merger Agreement), each share of Terminix common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive at the prior election of the holder, either: (x) 1.4899 American depositary shares of Rentokil Initial ("Rentokil Initial ADSs"); or (y) $34.57 in cash and 0.1447 Rentokil Initial ADSs.
F2 Each outstanding Terminix director deferred share equivalent ("Terminix DSE") was converted into an amount in cash of $38.29, and otherwise was paid on the same terms and conditions as applicable under the Terminix DSE award agreement.
F3 Each outstanding Terminix option then vested was converted into the right to receive an amount in cash of $38.29, less the applicable exercise price.

Remarks:

In connection with the transaction, the reporting person ceased to be a Section 16 reporting person.